Altacor Broadens Portfolio With Intraocular Lens (IOL) Delivery

CAMBRIDGE, England, April 21, 2011 - Altacor announces that it has today concluded an exclusive,
worldwide licensing agreement with the Swiss based company Ophthalmopharma
for its proprietary, preloaded injector for delivery of intraocular lens in
cataract and corrective lens replacement surgery (currently known as
SOLO(R)). This is the first in a series of transactions between Altacor and
Ophthalmopharma in relation to its entire portfolio of ophthalmic products.
Under the terms of the agreement, Altacor has assumed responsibility for all
aspects of development, IP and commercialisation of the products.

SOLO(R) is pre-loaded single-use intraocular lens (IOL)
injector which can be used to deliver both hydrophobic and hydrophilic
intraocular lenses (IOL's). It has broad potential applications in cataract
surgery and the increasingly performed lens replacement procedures for
correction of vision defects. SOLO's design includes a patented novel
mechanism which ensures rapid and efficient placement of IOL's, lower risk of
contamination, higher comfort to the patient and a low incidence of damaged
lenses during insertion.

Dr Fran Crawford, CEO of Altacor welcomed the addition of this
product to Altacor's commercial portfolio which is a particularly exciting
opportunity in the USA where a growing cataract market and decreasing
reimbursement require physicians to constantly seek improvements in
efficiency and safety. This is one of a number of corporate transactions that
will advance the company towards its strategic goal of becoming a European
Specialty Pharma ophthalmology company with growing sales and a strong
pipeline.

Dr. Patrik Frei, Chairman of Ophthalmopharma said "I am very
happy to have found such a well suited partner for this very interesting
product. I firmly believe this to be a complementary product to Altacors'
pipeline and I am confident that this will deliver value to both
Ophthalmopharma and Altacor."

About Altacor

Altacor is an ophthalmic specialty pharmaceutical company with marketed
products and a diverse development pipeline. The products are focused in the
following sub therapeutic areas: ocular surface disease, ocular
anti-infection and glaucoma. The company differentiates products through, for
example, formulation or reprofiling. ALT 005 (surgical) and ALT 020 (ocular
anti-infection), ALT 022 glaucoma and ALT 401 for prevention of scarring in
glaucoma surgery are examples. Altacor has five products marketed in the UK
and Ireland (Clinitas and Clinitas range) which are commercialised through
its own sales and marketing organisation and network. Clinitas and Clinitas
GEL are prescription products, the former is for moderate dry eye conditions
and has a uniquely high concentration of hyaluronic acid (0.4%) in the UK, it
is gaining acceptance by clinicians nationwide. The OTC Clinitas range
comprises Clinitas Hydrate, Clinitas Soothe and Clinitas Ultra 3 which
together address the major causes of dry eye.

For further details contact: Francesca E Crawford (CEO) +44(0)1223-421411